7.05
-0.14 (-1.95%)
前收盘价格 | 7.19 |
收盘价格 | 7.30 |
成交量 | 4,049 |
平均成交量 (3个月) | 28,506 |
市值 | 72,323,840 |
价格/销量 (P/S) | 0.960 |
股市价格/股市净资产 (P/B) | 0.760 |
52周波幅 | |
利润日期 | 3 Dec 2024 |
营业毛利率 | -111.18% |
营业利益率 (TTM) | -82.06% |
稀释每股收益 (EPS TTM) | -5.71 |
季度收入增长率 (YOY) | -7.30% |
总债务/股东权益 (D/E MRQ) | 15.92% |
流动比率 (MRQ) | 3.11 |
营业现金流 (OCF TTM) | -144.48 M |
杠杆自由现金流 (LFCF TTM) | 7.71 M |
资产报酬率 (ROA TTM) | -30.91% |
股东权益报酬率 (ROE TTM) | -68.89% |
市场趋势
短期 | 中期 | ||
行业 | Diagnostics & Research (US) | 看跌 | 混合的 |
Diagnostics & Research (全球的) | 看跌 | 混合的 | |
股票 | Burning Rock Biotech Limited | 混合的 | 混合的 |
AIStockmoo 评分
分析师共识 | -2.0 |
内部交易活动 | NA |
价格波动 | -2.0 |
技术平均移动指标 | 2.5 |
技术振荡指标 | 2.0 |
平均 | 0.13 |
Burning Rock Biotech Ltd is a cancer diagnostics company. It is a NGS-based cancer therapy selection company. Its cancer therapy selection platform is built upon advanced proprietary technologies, comprehensive portfolio of products and a two-pronged market-driven commercial infrastructure addressing both larger hospitals through our in-hospital model and smaller hospitals through our central laboratory model. It had three operating segments, including Central laboratory business, In-hospital business and Pharma research and development services. It generates the majority of its revenue from Central laboratory business. Its products are Pan-HEME, OncoScreen-WES, brPROPHET, OncoScreen Plus, and others. |
|
部门 | Healthcare |
行业 | Diagnostics & Research |
内部持股比例 | 0.04% |
机构持股比例 | 60.95% |
所有权
姓名 | 日期 | 持有股份 |
---|---|---|
Shen Neil Nanpeng | 30 Sep 2024 | 885 |
该时间范围内无数据。
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能(AI)模型生成的,请谨慎解读。
投资组合